4/A: Vaccinex CEO Corrects Stock Option Details in Amended SEC Filing
SEC Filing (Form 4/A)
Maurice Zauderer, CEO of Vaccinex, files an amended SEC Form 4 to correct the transaction date, exercise price, and expiration date of a stock option grant.
Summary
- Maurice Zauderer, the President and CEO of Vaccinex, Inc., filed an amended Form 4 with the SEC.
- The amendment corrects errors in the original filing regarding a stock option grant.
- The corrected transaction date is March 21, 2024, not March 20, 2024.
- The corrected exercise price is $8.21 per share, not $9.15.
- The corrected expiration date is March 21, 2034, not March 20, 2029.
- The stock option grant was for 1,877 shares of common stock and vests over four years from the grant date.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing correcting administrative errors. It doesn't contain information that would significantly impact investor sentiment positively or negatively.
Industry Context
This filing is a routine disclosure related to executive compensation and is required by the SEC for publicly traded companies.
Key Dates
| Date | Description |
|---|---|
| 03/21/2024 | Corrected transaction date of the stock option grant. |
| 03/21/2024 | Stock option grant date. |
| 03/22/2024 | Date of original Form 4 filing (amended). |
| 03/21/2034 | Corrected expiration date of the stock option. |
| 05/14/2024 | Date of amended Form 4 filing. |
Keywords
Vaccinex, VCNX, SEC Form 4, Stock Option, Maurice Zauderer, Amendment, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.